Bladder

Localized Disease

PD-L1–selected muscle invasive bladder cancer (MIBC) Status Post Cystectomy

BLDR0017
Phase III
Atezolizumab vs Observation as Adjuvant Tx in PD-L1 Selected High Risk Bladder Cancer
Pt: Srinivas Genentech

BLDR0025
Phase Ib/II
Atezolizumab +/- Bacille Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer
Pt: Skinner F. Hoffmann-LaRoche

BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) OR BCG-relapsed NMIBC OR Very high risk (VHR) BCG-native NMIBC

Unwilling or Unable to receive additional Bacille Calmette-Guerin

ECOG-ACRIN- S1605
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Pt: Skinner ECOG-ACRIN

No prior BCG, Non-invasive bladder cancer

ECOG-ACRIN- S1602
Phase III Different Strains of BCG +/- Vaccine in High Grade Non-Muscle Invasive Bladder Cancer
Pt: Skinner ECOG-ACRIN

KEY

- | Optional Path
- | Extension Study
Link | Trial Posting
- | Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu